Acta Pharmaceutica最新文献

筛选
英文 中文
Relaxin-2 protects synaptic integrity via hippocampal NLRP3-mTOR-autophagy pathways in an age-dependent Alzheimer-like model. 松弛素-2通过海马nlrp3 - mtor自噬通路在年龄依赖性阿尔茨海默病样模型中保护突触完整性
IF 1.8 4区 医学
Acta Pharmaceutica Pub Date : 2026-10-26 DOI: 10.2478/acph-2026-0023
Daohe Wang, Zhigang Zhao, Yumei Ding
{"title":"Relaxin-2 protects synaptic integrity <i>via</i> hippocampal NLRP3-mTOR-autophagy pathways in an age-dependent Alzheimer-like model.","authors":"Daohe Wang, Zhigang Zhao, Yumei Ding","doi":"10.2478/acph-2026-0023","DOIUrl":"https://doi.org/10.2478/acph-2026-0023","url":null,"abstract":"<p><p>Alzheimer disease (AD) is associated with age-related synaptic degeneration, neuroinflammation, and impaired autophagy. The present study aimed to investigate the age-dependent neuroprotective effects of relaxin-2 (RLN2) in amyloid-beta 1-42 (Aβ<sub>1</sub> <sub>-</sub> <sub>42</sub>)-induced AD-like pathology and hypothesised that RLN2 would provide greater therapeutic benefit in young than aged mice. Young (3-4 months) and aged (12-14 months) mice were intracerebrally (<i>i.c.</i>) injected with amyloid-β (Aβ<sub>1</sub> <sub>-</sub> <sub>42</sub>) to develop an AD-like phenotype and treated with RLN2 or a control. Western blot analysis of hippocampal tissues was performed to assess the expression levels of ionised calcium-binding adaptor molecule 1 (Iba1) (microglial activation marker), NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome components, and mechanistic target of rapamycin (mTOR) pathway activity. Neuroinflammation was determined by interleukin-1 beta (IL-1β) and tumour necrosis factor-alpha (TNF-α), while synaptic integrity was assessed by synaptophysin and PSD-95. The Morris Water Maze (MWM) and Novel Object Recognition (NOR) tests were used to measure cognitive and memory performance. Neuroinflammation markers IL-1β and TNF-α were significantly elevated in Aβ<sub>1</sub> <sub>-</sub> <sub>42</sub>-injected mice, with aged mice showing a greater increase than young mice. RLN2 treatment markedly reduced IL-1β and TNF-α levels in young mice, whereas the reduction was limited in aged mice. RLN2 treatment had a significant inhibitory effect on hippocampal NLRP3 signalling, reduced mTOR signalling, modulated autophagy-related protein expression, preserved synaptic proteins, and improved cognitive and memory performance (decrease in the MWM escape latency and increase in the NOR discrimination index). RLN2 was not effective in the aged mice, and there was persistent inflammatory activation, impaired autophagy, minimal improvement in synaptic recovery, and a moderate improvement in cognition. These findings suggest that RLN2 could be a potential therapeutic candidate for early-stage AD by targeting neuroinflammation, mTOR-mediated autophagy-related dysregulation, and synaptic loss, while also potentially providing a basis for age-based stratification of treatment responsiveness; however, further studies are required to determine its utility as a biomarker of treatment response or disease progression. Overall, RLN2 exerted neuro-protective effects in <i>i.c.</i> Aβ<sub>1</sub> <sub>-</sub> <sub>42</sub>-induced AD-like pathology in an age-dependent manner.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gentiopicroside suppresses cell proliferation, migration, and invasion via inhibition of the HGF/PI3K/Akt pathway in clear cell renal cell carcinoma. Gentiopicroside通过抑制透明细胞肾细胞癌中HGF/PI3K/Akt通路抑制细胞增殖、迁移和侵袭。
IF 1.8 4区 医学
Acta Pharmaceutica Pub Date : 2026-10-26 DOI: 10.2478/acph-2026-0032
Xiaoling Wang, Zhijie Song, Nannan Zhang, Chunyan Zhang, Chunying Bai, Xianjun Liu
{"title":"Gentiopicroside suppresses cell proliferation, migration, and invasion <i>via</i> inhibition of the HGF/PI3K/Akt pathway in clear cell renal cell carcinoma.","authors":"Xiaoling Wang, Zhijie Song, Nannan Zhang, Chunyan Zhang, Chunying Bai, Xianjun Liu","doi":"10.2478/acph-2026-0032","DOIUrl":"https://doi.org/10.2478/acph-2026-0032","url":null,"abstract":"<p><p>Clear cell renal cell carcinoma (ccRCC) is the most common malignant renal tumour; however, effective therapeutic drugs are still limited. Gentiopicroside, a naturally occurring iridoid glycoside, has demonstrated antitumour activity, but its effects on ccRCC remain unclear. This study aimed to evaluate the role of gentiopicroside in ccRCC and elucidate its underlying mechanisms. Cell viability and proliferation were measured using the CCK-8 assay, while wound healing and Transwell assays evaluated cell migration and invasion, respectively. Bioinformatic analysis of high-throughput gene expression data was performed to predict the mechanisms underlying the anti-ccRCC effects of gentiopicroside. qPCR and Western blotting were used to determine mRNA and protein levels, respectively. The results demonstrated that gentiopicroside dose-dependently suppressed proliferation, migration, and invasion of ccRCC cells. High-throughput bioinformatic analysis suggested that the PI3K/Akt pathway and HGF may mediate the regulatory effects of gentiopicroside in ccRCC. Gentiopicroside inhibited the PI3K/Akt pathway, and activation of this pathway reversed its suppressive effects on malignant phenotypes of ccRCC cells. Furthermore, gentiopicroside downregulated HGF expression, whereas HGF overexpression counteracted gentiopicroside--induced inhibition of the PI3K/Akt pathway and malignant phenotypes. In conclusion, gentiopicroside inhibits ccRCC cell proliferation, migration, and invasion <i>via</i> the HGF/PI3K/Akt pathway. These findings not only propose a novel candidate drug for ccRCC treatment but also advance our understanding of the bioactivity and mechanisms of gentiopicroside.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating network pharmacology and experimental validation reveals PI3K/AKT as a critical pathway in pachymic acid-induced inhibition of hepatocellular carcinoma. 结合网络药理学和实验验证,发现PI3K/AKT在厚霉素酸诱导的肝细胞癌抑制中起关键作用。
IF 1.8 4区 医学
Acta Pharmaceutica Pub Date : 2026-10-26 DOI: 10.2478/acph-2026-0033
Jun Liang, Hongyu Zhang, Shixin Pan, Tao Si, Minzhong Tang, Zheng Peng
{"title":"Integrating network pharmacology and experimental validation reveals PI3K/AKT as a critical pathway in pachymic acid-induced inhibition of hepatocellular carcinoma.","authors":"Jun Liang, Hongyu Zhang, Shixin Pan, Tao Si, Minzhong Tang, Zheng Peng","doi":"10.2478/acph-2026-0033","DOIUrl":"https://doi.org/10.2478/acph-2026-0033","url":null,"abstract":"<p><p>Pachymic acid (PA), a natural lanost-8-ene-type triterpenoid isolated from <i>Poria cocos</i>, exhibits diverse pharma cological activities, including anti-oxidant, anti-inflammatory, antiaging, and hypnotic effects. Emerging evi dence has highlighted its potential anticancer properties, particularly its ability to suppress the proliferation of various cancer cell lines, though the underlying mechanisms remain largely undefined. In this study, we employed a network pharmacology approach to explore the anti-hepatocellular carcinoma (anti-HCC) effects of PA. GO and KEGG enrichment analyses identified the PI3K/AKT signalling pathway as a key candidate mediating PA's activity in liver cancer cells. This prediction was subsequently validated by Western blotting, which confirmed that PA markedly inhibited the growth of HepG2 HCC cells through suppression of the PI3K/AKT pathway, as evidenced by reduced AKT phosphorylation. Collectively, our findings provide new insights into the anticancer mechanisms of PA and support its potential as a promising candidate for novel anti-HCC therapies.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Size exclusion chromatography as a characterization tool for quality control of marine biopharmaceutical keyhole limpet hemocyanin. 粒径排斥色谱法用于海洋生物制药锁孔帽贝血青素的质量控制。
IF 1.8 4区 医学
Acta Pharmaceutica Pub Date : 2026-10-23 DOI: 10.2478/acph-2026-0030
Paula Cermakova, Petra Majerova, Andrej Kovac, Juraj Piestansky
{"title":"Size exclusion chromatography as a characterization tool for quality control of marine biopharmaceutical keyhole limpet hemocyanin.","authors":"Paula Cermakova, Petra Majerova, Andrej Kovac, Juraj Piestansky","doi":"10.2478/acph-2026-0030","DOIUrl":"https://doi.org/10.2478/acph-2026-0030","url":null,"abstract":"<p><p>Keyhole limpet hemocyanin is a large metalloprotein present in hemolymph of the mollusk <i>Megathura crenulata</i>. This protein is highly immunogenic, making it very attractive to the biopharmaceutical industry, where it is used as a carrier protein for haptens, an adjuvant, or as a stand-alone biologic for the treatment of various cancer diseases. The structural complexity of such immunogenic protein makes its characterization and quality control very challenging. Here, we developed, optimized and validated a size exclusion chromatography approach for quality control of keyhole limpet hemocyanin products. The separation procedure was performed on an Acquity UPLC BEH450 SEC column with pore size of 450 Å in a mobile phase composed of 25 mmol L<sup>-</sup> <sup>1</sup> phosphate buffer (pH 6.8) with 250 mmol L<sup>-</sup> <sup>1</sup> NaCl. These conditions led to appropriate elution of the analysed protein. The developed method showed very promising values of validation parameters, such as coefficient of de termination (<i>R</i> <sup>2</sup> = 0.9997), sensitivity (limit of detection 10.21 μg mL-1, limit of quantitation 31.25 μg mL<sup>-</sup> <sup>1</sup>), precision (repeatability 0.3-2.5 %, intermediate precision 1.1-4.2 %), and accuracy (100.4-102.8 %). The developed method was used to determine the content of keyhole limpet hemocyanin in three commercially available samples obtained from various suppliers. The determined content ranged from 20.08 to 22.91 mg per vial.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanocarrier based drug delivery for rheumatoid arthritis: Current strategies and future directions. 基于纳米载体的类风湿性关节炎药物递送:当前策略和未来方向。
IF 1.8 4区 医学
Acta Pharmaceutica Pub Date : 2026-10-23 DOI: 10.2478/acph-2026-0028
Na Li, Zefang Qu, Daodong Du
{"title":"Nanocarrier based drug delivery for rheumatoid arthritis: Current strategies and future directions.","authors":"Na Li, Zefang Qu, Daodong Du","doi":"10.2478/acph-2026-0028","DOIUrl":"https://doi.org/10.2478/acph-2026-0028","url":null,"abstract":"<p><p>The application of nanotechnology in drug delivery systems has attracted considerable scientific interest, particularly with respect to improving the therapeutic efficacy and safety profiles of pharmacological agents. This review critically examines nanotechnology-based drug delivery systems for the management of rheumatoid arthritis (RA), a chronic systemic autoimmune disease characterized by persistent synovial inflammation, progressive joint destruction, and significant extraarticular sequelae. Conventional pharmacological strategies such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and biological disease-modifying anti-rheumatic drugs (bDMARDs) provide disease control but are associated with significant adverse effects upon prolonged use, inadequate joint specific drug concentrations, and limited responsiveness in a subset of patients. Nanotechnology offers a compelling therapeutic solution by enabling targeted drug delivery to inflamed synovial tissue, thereby enhancing bioavailability, reducing systemic toxicity, and extending drug half-life. This review discusses diverse nanotechnology platforms, such as liposomes, dendrimers, polymeric nanoparticles, hydrogels, metal, inorganic nanoparticles, nucleic acid-based carriers, and stimuli-responsive nanocarriers evaluated for RA treatment. The evidence underscores the potential of these systems to overcome the limitations of traditional therapies and to facilitate precision therapeutics in RA. The review also addresses existing challenges in nanomedicine translation, such as inter-patient variability, protein corona formation, endosomes (as a barrier), biocompatibility, and the need for rigorous clinical validation, while outlining future directions including exosome mediated delivery, biomimetic nano-carriers, and stimuli-responsive platforms.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260549","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Syringin inhibits insulin resistance through the PI3K/AKT pathway. 紫丁香素通过PI3K/AKT通路抑制胰岛素抵抗。
IF 1.8 4区 医学
Acta Pharmaceutica Pub Date : 2026-10-13 DOI: 10.2478/acph-2026-0024
Haitao Wang, Jianjian Han, Lu Yun, Xiaolei Wang
{"title":"Syringin inhibits insulin resistance through the PI3K/AKT pathway.","authors":"Haitao Wang, Jianjian Han, Lu Yun, Xiaolei Wang","doi":"10.2478/acph-2026-0024","DOIUrl":"https://doi.org/10.2478/acph-2026-0024","url":null,"abstract":"<p><p>This study aims to investigate the effects of syringin on insulin resistance (IR) and its mechanisms using an IR model in HepG2 cells. IR was induced by 10<sup>4</sup> mol L<sup>-1</sup> insulin for 24 h, followed by syringin treatment at various concentrations for 48 h. Levels of glucose, triglycerides, TNF-α, IL-6, and GRP78 were measured, and protein expression of IRS-1, p-IRS-1, PI3K, p-PI3K, AKT, p-AKT, FoxO1, and p-FoxO1 was analysed by Western blot. Compared with controls, the IR model showed significant increases in glucose, triglycerides, TNF-α, IL-6, GRP78, and decreases in p-IRS1/IRS1, p-PI3K/PI3K, and p-AKT/AKT, with increased p-FoxO1/FoxO1 (all <i>p</i> < 0.01). Syringin (50-200 μg mL<sup>-1</sup>) significantly lowered glucose, triglycerides, TNF-α, IL-6, and GRP78, and reversed these signalling changes by upregulating p-IRS1/IRS1, p-PI3K/PI3K, p-AKT/AKT and downregulating p-FoxO1/FoxO1 (<i>p</i> < 0.05). Syringin effectively ameliorates insulin resistance in HepG2 cells, lowers glucose and triglycerides, and improves glucose-lipid metabolism, likely <i>via</i> the PI3K/AKT pathway.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First-in-class HPLC-fluorescence method for quantification of roscovitine in plasma: Greenness assessment and application to pharmacokinetic studies in rats. 高效液相色谱-荧光定量血浆中罗斯维汀的方法:绿度评价及其在大鼠药代动力学研究中的应用。
IF 1.8 4区 医学
Acta Pharmaceutica Pub Date : 2026-10-13 DOI: 10.2478/acph-2026-0029
Ibrahim A Darwish, Nourah Z Alzoman
{"title":"First-in-class HPLC-fluorescence method for quantification of roscovitine in plasma: Greenness assessment and application to pharmacokinetic studies in rats.","authors":"Ibrahim A Darwish, Nourah Z Alzoman","doi":"10.2478/acph-2026-0029","DOIUrl":"https://doi.org/10.2478/acph-2026-0029","url":null,"abstract":"<p><p>This research introduces a first-in-class high-performance liquid chromatography with fluorescence detection (HPLC-FD) method for the reliable quantification of ROS in plasma. The method relies on the native fluorescence of ROS, with excitation and emission set at 280 nm and 340 nm, resp. Sample preparation involved a simple one-step protein precipitation with methanol. Chromatographic resolution of ROS and pemigatinib (PEM), which served as the internal standard (IS), was achieved using Zorbax Eclipse Plus C18 HPLC column. The mobile phase consisted of methanol and formate buffer solution. The method was validated in compliance with ICH M10 guidelines. It showed linearity across concentration range of 50-1,500 ng mL<sup>-1</sup> (<i>R</i>² = 0.9991), with a lower limit of quantitation of 50 ng mL<sup>-1</sup>. Accuracy ranged from 96.8 to 103.4 %, and intra- and inter-day precision (RSD) were between 3.2 and 6.1 %. The method was successfully applied to quantify ROS in plasma samples from rats following administration of a single oral dose (25 mg kg<sup>-1</sup>), enabling the determination of key pharmacokinetic parameters, including <i>C</i> <sub>max</sub> (361.31 ng mL<sup>-1</sup>), <i>t</i> <sub>max</sub> (1.75 h, <i>t</i> <sub>½</sub> (2.867 h), <i>V</i> <sub>d</sub> (0.077 L kg<sup>-1</sup>), <i>CL</i> (0.018 L h<sup>-1</sup> kg<sup>-1</sup>), <i>AUC</i> (ng h mL<sup>-1</sup>) and and <i>MRT</i> (h). The greenness and practical applicability of the method were confirmed using four comprehensive independent metric tools. In comparison to previously reported bioanalytical approaches, the proposed method offers several practical advantages, such as reduced complexity and cost, a shorter run time, full validation, established greenness, and suitability for the clinical laboratory setting.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse event reporting of golimumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database. 戈利姆单抗不良事件报告:FDA不良事件报告系统(FAERS)数据库的歧化分析。
IF 1.8 4区 医学
Acta Pharmaceutica Pub Date : 2026-10-13 DOI: 10.2478/acph-2026-0022
Wenjie Ma, Nuan Jia, Hui Liao, Zhilei Li, Xiaodan Li
{"title":"Adverse event reporting of golimumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.","authors":"Wenjie Ma, Nuan Jia, Hui Liao, Zhilei Li, Xiaodan Li","doi":"10.2478/acph-2026-0022","DOIUrl":"https://doi.org/10.2478/acph-2026-0022","url":null,"abstract":"<p><p>This study conducted a retrospective disproportionality analysis of 50,031 adverse drug event (ADE) reports from the FDA Adverse Event Reporting System (FAERS) database spanning Q2 2009 to Q3 2025, in which golimumab was identified as the primary suspect drug. Four disproportionality algorithms were simultaneously applied: the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS). A total of 397 positive signals were identified across 25 system organ classes (SOCs). The SOCs with concordant positive signals across all four algorithms were identified for infections and infestations and surgical and medical procedures. High-frequency signals included pneumonia, lower respiratory tract infection, influenza, nasopharyngitis, sinusitis and cellulitis. Comparison with the current prescribing information revealed several previously undocumented ADEs, including urinary tract infection, ear infection, flavivirus infection, Zika virus infection and Dengue fever. Twenty-nine positive malignancy signals absent from the prescribing information were identified, including basal cell carcinoma, colorectal cancer, cervical cancer and breast cancer. Time-to-onset analysis revealed that the risk of ADEs was the highest within the first few months of treatment initiation. Clinicians should rigorously monitor for infectious complications and malignancies when prescribing golimumab to ensure patient safety.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149178262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analytical approach for conversion of conventional to green RP-HPLC methods for analysis of lipophilic neutral and basic active pharmaceutical ingredients. 亲脂性中性和碱性活性药物成分分析的传统RP-HPLC法向绿色RP-HPLC法转化的分析方法。
IF 1.8 4区 医学
Acta Pharmaceutica Pub Date : 2026-09-23 DOI: 10.2478/acph-2026-0021
Bojana Vulovska Trifunovska, Ana Atanasova, Packa Antovska, Katerina Brezovska, Aneta Dimitrovska, Natalija Nakov
{"title":"Analytical approach for conversion of conventional to green RP-HPLC methods for analysis of lipophilic neutral and basic active pharmaceutical ingredients.","authors":"Bojana Vulovska Trifunovska, Ana Atanasova, Packa Antovska, Katerina Brezovska, Aneta Dimitrovska, Natalija Nakov","doi":"10.2478/acph-2026-0021","DOIUrl":"https://doi.org/10.2478/acph-2026-0021","url":null,"abstract":"<p><p>Conventional RP-HPLC methods in pharmaceutical industry still dominantly rely on hazardous solvents like methanol (MeOH) and acetonitrile (ACN), presenting significant environmental and safety challenges. Although ethanol (EtOH) is recognized as greener alternative, isoeluotropic relationships between EtOH and these conventional solvents will broaden its implementation in routine HPLC analyses. To address this issue, the study presents an empirical approach using volu-metric fraction (<i>φ</i>) equivalence to establish initial chromatographic conditions, enabling predictable substitution of MeOH and ACN with EtOH in the LC mobile phase without altering other chromatographic parameters. The approach was established using adsorption (log-log) retention model across multiple C<sub>18</sub> stationary phases, applicable for lipophilic neutral and basic active pharmaceutical ingredients (APIs). For neutral APIs, <i>φ</i> MeOH ≈ 1.6 <i>φ</i> EtOH and <i>φ</i> ACN ≈ 1.1 <i>φ</i> EtOH, while for basic APIs <i>φ</i> MeOH ≈ 1.5 <i>φ</i> EtOH and <i>φ</i> ACN ≈ 1.0 <i>φ</i> EtOH. The general applicability was confirmed under isocratic conditions by successfully converting conventional RP-HPLC methods for an independent set of APIs into green, EtOH-based alternatives. Notably, this work extends previous research focused on lipophilic acidic to neutral and basic APIs, broadening its utility for the most widely used APIs in the pharmaceutical industry. The proposed framework supports sustainable analytical practices and improves laboratory safety without extensive method redevelopment.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149023636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A meta-analysis of the effects of Zingiber officinale on metabolic indices among patients with type 2 diabetes. 生姜对2型糖尿病患者代谢指标影响的荟萃分析。
IF 1.8 4区 医学
Acta Pharmaceutica Pub Date : 2026-09-23 DOI: 10.2478/acph-2026-0020
Qianjun Li, Min Li, Misbah Ullah Khan, Wei Cai
{"title":"A meta-analysis of the effects of <i>Zingiber officinale</i> on metabolic indices among patients with type 2 diabetes.","authors":"Qianjun Li, Min Li, Misbah Ullah Khan, Wei Cai","doi":"10.2478/acph-2026-0020","DOIUrl":"https://doi.org/10.2478/acph-2026-0020","url":null,"abstract":"<p><p>The metabolic effects of ginger (<i>Zingiber officinale</i>) on type 2 diabetes have been increasingly assessed in clinical trials, but the results remain inconsistent. In this updated meta-analysis, the Cochrane Library, Scopus, PubMed, Web of Science, and Google Scholar were searched from the inception to November 12, 2025, to find randomised controlled trials comparing the effect of ginger and placebo on the metabolic indexes of patients with type 2 diabetes. Pooling data from 13 articles with 837 participants indicated that treatment with ginger significantly decreased fasting blood sugar (FBS) (weighted mean difference (WMD) -16.22 mg per 100 mL, 95 % confidence interval (CI) (-25.49, -6.95), I<sup>2</sup> = 85.67 %), hemoglobin A1c (HbA1c) (WMD -0.49 %, 95 % CI (-0.86, -0.12), I<sup>2</sup> = 98.14 %), triglyceride level (WMD -17.04 mg per 100 mL, 95 % CI (-28.61, -5.47), I<sup>2</sup> = 71.30 %), and low-density lipoprotein cholesterol (LDL-C) (WMD -5.5 mg per 100 mL, 95 % CI (-10.98, -0.01), I<sup>2</sup> = 83.99 %). However, the beneficial effects of ginger on body mass index (BMI), homeostasis model assessment for insulin resistance (HOMA-IR), total cholesterol, high-density lipo-protein-cholesterol (HDL-C), and systolic and diastolic blood pressure did not meet the threshold of statistical significance. Ginger was more effective at a daily dose of less than 2000 mg (powdered rhizome of <i>Zingiber officinale</i> administered orally) and in males, individuals younger than 54 years, and individuals with a baseline HbA1c of more than 8 %.</p>","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书